Cytophage Technologies Ltd. is a biotechnology company that focuses on developing innovative solutions to combat bacterial infections. The primary purpose of Cytophage Technologies Ltd. is to create engineered bacteriophages, which are viruses that specifically target and destroy bacteria. This cutting-edge approach serves as an alternative treatment to traditional antibiotics, addressing the growing global challenge of antibiotic resistance. The company's advanced biotechnological research significantly impacts healthcare sectors, particularly in clinical settings, agriculture, and food safety. By providing targeted and adaptable solutions, Cytophage Technologies Ltd. plays a crucial role in developing next-generation therapeutics. Additionally, its innovations contribute to reducing healthcare costs and improving patient outcomes by offering sustainable infection management strategies. Headquartered in Canada, this firm embodies a forward-thinking approach in the ongoing battle against pathogens, holding the potential to revolutionize infection treatments worldwide."}